US12268662 — Formulations comprising carbachol and brimonidine to enhance anti- presbyopia effects
Method of Use · Assigned to Visus Therapeutics Inc · Expires 2042-11-10 · 16y remaining
What this patent protects
This patent protects ophthalmic formulations containing carbachol and brimonidine for treating presbyopia and other ophthalmic conditions.
USPTO Abstract
The present disclosure is directed to ophthalmic formulations comprising carbachol, processes for preparing ophthalmic formulations comprising carbachol, and methods of treating presbyopia and other ophthalmic conditions by administering ophthalmic formulations comprising carbachol to a subject in need thereof.
Drugs covered by this patent
- Alphagan (BRIMONIDINE TARTRATE) · Senju Pharmaceutical Co., Ltd
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3741 |
— | Alphagan |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.